key: cord-0947957-8qpkyu1p authors: Pakdel, Farzad; Ahmadikia, Kazem; Salehi, Mohammadreza; Tabari, Azin; Jafari, Rozita; Mehrparvar, Golfam; Rezaie, Yasaman; Rajaeih, Shahin; Alijani, Neda; Barac, Aleksandra; Abdollahi, Alireza; Khodavaisy, Sadegh title: Mucormycosis in patients with COVID‐19: A cross‐sectional descriptive multicenter study from Iran date: 2021-06-07 journal: Mycoses DOI: 10.1111/myc.13334 sha: 1a9f4ea67814561fb5618488a3578193684d62f2 doc_id: 947957 cord_uid: 8qpkyu1p PURPOSE: The aim of the study was to report clinical features, contributing factors and outcome of patients with coronavirus disease 2019 (COVID‐19) associated mucormycosis (CAM). METHODS: A cross‐sectional descriptive multicenter study was conducted on patients with biopsy‐proven mucormycosis with RT‐PCR confirmed COVID‐19 from April to September 2020. Demographics, the time interval between COVID‐19 and mucormycosis, underlying systemic diseases, clinical features, course of disease and outcomes were collected and analyzed. RESULTS: Fifteen patients with COVID‐19 and rhino‐orbital mucormycosis were observed. The median age of patients was 52 years (range 14‐71) and 66% were male. The median interval time between COVID‐19 disease and diagnosis of mucormycosis was seven (range: 1‐37) days. Among all, 13 patients (86%) had diabetes mellitus, while 7n (46.6%) previously received intravenous corticosteroid therapy. Five patients (33%) underwent orbital exenteration, while seven (47%) patients died from mucormycosis. Six patients (40%) received combined anti‐fungal therapy and none that received combined anti‐fungal therapy died. CONCLUSION: Clinicians should be aware that mucormycosis may be complication of COVID‐19 in high‐risk patients. Poor control of diabetes mellitus is an important predisposing factor for CAM. Systematic surveillance for control of diabetes mellitus, and educating physician about the early diagnosis of CAM are suggested. 237 blood acidosis in severe form of COVID-19 and elevated levels of serum ferritin cannot be ignored for 238 mucormycosis susceptibility. 4, 6, 19 The presence of DM along with other COVID-19 associated medications and 239 complications could be important risk factors for mucormycosis. Two of our subjects (13.3%) were undergoing 240 chemotherapy due to acute myeloid leukemia (AML) and had profound neutropenia ( 100 cells/mm3). 241 Regardless of COVID-19 status and receiving corticosteroids, as affirmed by our data, patients with profound 242 neutropenia and those suffering from acute hematological malignancies (HMs) are at high risk to develop 243 mucormycosis. 19 Besides, Hoenigl et al. equally noted that 5/80 patients (6.2%) were suffering from HMs. 244 However, none of 42 COVID-19 associated ROM and ROCM previously reported cases were suffering from 245 either neutropenia or HM (Table 4 ). Although ROCM is the commonest manifestation of mucormycosis in 246 patients with poorly controlled diabetes, the lung is the more frequent site of involvement in patients with 247 HMs. 21, 24 The early manifestation of mucormycosis in 73% of our patients was orbital apex syndrome. This 248 shows a rapid progression of the disease to orbit at presentation. Nonetheless, no case of ROCM was observed 249 in our investigation that was not in agreement with the observation of Hoenigl et al. 20 reporting rhino-orbital 250 cerebral infection as the most commonly presented form of mucormycosis in COVID-19 patients (59/80, 74%). 251 In the present study, despite of antifungal treatment and surgical measures, the mortality rate was as high as 47 252 %. Given the acuteness and aggressiveness of the infection, timely diagnosis for prompt antifungal therapy is 253 highly recommended in order to decrease the rate of mortality. 25 Interestingly, 100 % of our patients who 254 received combined antifungal treatment survived (Apendix -1). More so, 75% of 8 COVID-19 associated ROM 255 and ROCM previously reported cases who received combined antifungal treatment survived (Table 4) This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved Fifty-eight patients were evaluated with suspicion of mucormycosis in these centers during the period time, 158 finally fifteen patients with laboratory confirmed COVID-19 and mucormycosis were included in this study No patient had pulmonary mucormycosis. The most common 180 form of paranasal sinus involvement was pansinusitis. In ten (67%) cases, mucormycosis was extended to skull 181 base spaces. Among patients, 53.3% had pterygopalatine fossa involvement. Cavernous sinus involvement, 182 developed in seven cases (46%). Clinical, radiological, and histological features in a patient with COVID-19 183 associated mucormycosis are shown in Figure 1. All of the patients were treated with intravenous amphotericin 184 B liposomal (Ambisome-Gilead Co.) (IV 5 mg/kg daily for 4-6 weeks) and four (27%) cases took oral 185 posaconazole (Noxafil-MSD Co.) (5 ml every 6 hours/ orally/for 2 weeks) (Combination antifungal agents as a 186 salvage treatment). Three (20%) patients took additional IV Caspofungin (Letocan-Nano Alvand Co.) (IV 70 187 mg stat and 50 mg daily) for 2 weeks (Table 2). The clinical and demographic characteristics of survivors and 188 non-survivors cases are compared in Table 3. Anti-fungal combination therapy was significantly associated with 189 better outcome (p=0.003). Seven patients (47%) succumbed as the result of mucormycosis. All patients with 190 ROM, SOM and SM underwent sinus debridement The all cause 30 days' mortality was 47%. No patient died secondary to known COVID-19 problems. 195 196 Discussion: Accepted Article This article is protected by copyright Although, the frequency of COVID-198 19 associated aspergillosis and candidiasis as the most frequent fungal complications in hospitalized COVID-19 199 patients have been highlighted in previous studies. 2, 3 In our previous investigation, 5% of COVID-19 patients 200 with history of corticosteroid treatment (47%) and broad-spectrum antibiotics (92%) developed oropharyngeal 201 candidiasis during hospital admission. 3 White et al. rated invasive fungal infections (IFIs) in 135 COVID-19 202 patients. They found a 26.7% incidence of IFIs (commonly aspergillosis (14.1%), or yeast infection In consistent with our observation, 209 the mean interval time between diagnosis of COVID-19 and clinical presentations of oropharyngeal candidiasis 210 and pulmonary aspergillosis was 8 and 11 days, respectively. 3, 18 Similarly, the result of our literature review of 211 42 COVID-19 associated ROM and ROCM cases demonstrated that mucormycosis was clinically diagnosed at 212 mean of 12.6 days (range= 0-42 days) after COVID-19 diagnosis 20 (Table 4). Therefore, based on the available 213 information, it seems that clinicians should be aware of possible occurrence of mucormycosis during the first to 214 second week of COVID-19 in high-risk patients. 6, 18 Although the immune responses alleviated and COVID-19 215 associated cytokine storm will be controlled ensuing corticosteroids usage, neutrophil immigration to mucosal 216 surfaces including sinus surfaces will be impaired and vulnerability for developing secondary infections like 217 mucormycosis will be simultaneously increased particularly in patients with DM. 6, 19 Overall, 47 % of our CAM 218 cases were receiving IV corticosteroid for COVID-19 treatment. Similarly, 40%-66 % of COVID-19 associated 219 aspergillosis and 47% of COVID-19 associated oropharyngeal candidiasis had history of steroids therapy It seems reasonable to apply systemic corticosteroids 225 cautiously in patients with COVID-19. 6 As evidenced previously, uncontrolled DM documented as the 226 prevailing risk factor implicated in mucormycosis development. 21, 22 In our study, 87 % of CAM cases had poor 227 controlled DM and one patient had DKA when mucormycosis diagnosed. The data was found to be in consistent 228 with the findings of our literature review regarding COVID-19 associated ROM and ROCM (38/42, 90%) 229 (Table 4) and Hoenigl et al.'s review (66/80, 82.5%) 20 . Geographically, diabetes was even more frequently 230 observed as risk factor in cases from India (32/34, 94 %) and USA (3/3, 100%) versus 3/5 (60%) among 231 COVID-19 associated ROM and ROCM cases reported from other countries (Table 4). Not only the 232 combination of corticosteroid therapy and diabetes mellitus can result in poor controlled status of diabetes and 233 synergistically paralyze the function of innate immunity, but also corticosteroid induced diabetes may be 234 occurred in healthy individuals who are receiving long term steroid therapy This article is protected by copyright. All This article is protected by copyright. All rights reserved